Jennifer A. Wellman

Jennifer A. Wellman is Chief Operating Officer at Akouos. She has twenty years of dedicated experience in adeno-associated viral (AAV) vector gene therapy research and development.

Prior to joining Akouos in early 2018, Ms. Wellman was Head of Product Development Strategy at Spark Therapeutics, Inc., of which she is a co-founder. While at Spark, and in her prior role as the Director of Regulatory for the Center for Cellular and Molecular Therapeutics at Children’s Hospital of Philadelphia, she led the regulatory and clinical development for several AAV gene therapies, including Luxturna®, the first FDA-approved gene therapy for a genetic disease. Prior to CHOP, Ms. Wellman served as Associate Scientist at Avigen, Inc., an early clinical-stage AAV gene therapy company.

Ms. Wellman holds an Honours B.S. in Microbiology and Immunology from Queen’s University (Canada) and an M.S. from the University of New Haven.